{"page":{"totalFilteredElements":24},"studies":[{"active":true,"description":"Stereotactic body\nradiotherapy (SBRT) for primary liver tumors (HepReg) - an International Multicentre Registry Collecting Data on Patients treated with SBRT for HCC","eudractNumber":null,"id":10200,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2026-03-02T13:32:31+01:00","shortTitle":"HepReg","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>Neuer zielgerichteter Therapieansatz beim IDH1 R132- mutierten Cholangiokarzinom</div><div>Evaluation der Wirksamkeit, Sicherheit und Lebensqualit&#228;t der Behandlung mit Ivosidenib</div>","eudractNumber":null,"id":10706,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-11-11T09:14:05+01:00","shortTitle":"IDHIRA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Neuer zielgerichteter Therapieansatz beim IDH1 R132- mutierten Cholangiokarzinom</div><div>Evaluation der Wirksamkeit, Sicherheit und Lebensqualit&#228;t der Behandlung mit Ivosidenib</div>","eudractNumber":null,"id":11564,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-10-06T09:14:01+02:00","shortTitle":"IDHIRA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<b>BZKF-Studie</b><div>A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER&#174;), in Patients with Recurrent and/or Refractory Solid Tumors<br /></div>","eudractNumber":"2021-004326-30","id":7252,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"},{"name":"MAGEA (Melanoma-associated Antigen)","id":"mt_245"},{"name":"MAGEA4","id":"mt_187"},{"name":"MAGEA8","id":"mt_188"}],"nctNumber":"NCT05359445","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2022-07-18T08:48:59+02:00","shortTitle":"IMA401-101","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"Jade - Klinische Forschungsplattform zur Behandlung und zum Ergebnis bei Patienten mit hepatozellul&#228;rem oder cholangiozellul&#228;rem Krebs<br />","eudractNumber":null,"id":6544,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT04510740","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-08-31T12:11:49+02:00","shortTitle":"JADE - Registerplattform Leberkrebs","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Data collection to design and validate LEOPARD predictive models of delisting in liver transplant candidates","eudractNumber":null,"id":11696,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT06675604","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2026-03-01T12:30:53+01:00","shortTitle":"Leopard","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab<br />for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC)","eudractNumber":"2022-001201-48","id":8455,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT05844046","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-10-10T10:57:44+02:00","shortTitle":"MONTBLANC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\">ENCLOSE (Klinische Studiengruppe NAFLD): CK18 M30 als\nnicht-invasiver Marker f&#252;r subklinische Zellsch&#228;digung &#8211; prospektive Analyse\ndes Langzeitverlaufes bei NAFLD</p>","eudractNumber":null,"id":2266,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[{"name":"Caspase-cleaved fragment of CK18 (M30)","id":"mt_271"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-07-01T12:46:03+02:00","shortTitle":"NAFLD CSG","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\" style=\"line-height:normal;\">National Center for Tumor Diseases / German Cancer Consortium (NCT/DKTK) Molecularly Aided Stratification for Tumor Eradication Research (MASTER)</p><p class=\"MsoNormal\" style=\"line-height:normal;\"><b>NCT MASTER Program</b></p>","eudractNumber":null,"id":4421,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2018-01-01T09:51:10+01:00","shortTitle":"NCT-Studie: MASTER Programm","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Prospektive Beobachtungsstudie mit Erstellung einer Biodatenbank zur Untersuchung potentieller Biomarker f&#252;r Risikostratifizierung, Therapiesteuerung und Vertr&#228;glichkeit in Patient*innen mit neuroendokrinen Neoplasien (NENReg)","eudractNumber":null,"id":11499,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-11-01T09:14:44+01:00","shortTitle":"NENReg","therapeutical":false,"therapyLines":[]}]}